Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

10K filing by OSIR shows it can help Japan with Radiation exposure treatment.

|Includes:AMGN, CBLI, DNDN, LLY, Osiris Therapeutics, Inc. (OSIR), PFE, SNY

A partial from 10k Filing :

In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In the first quarter of 2008, we were awarded a contract from the United States Department of Defense ("DoD") pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. Under the terms of the contract, the DoD will provide funding to us, and if we are successful in obtaining FDA approval for acute radiation syndrome, the contract provides for the purchase of up to 20,000 doses of Prochymal, at $10,000 per dose. Under the terms of this contract, we recognized $470,000 in revenue in fiscal 2010, $2.9 million in revenue in fiscal 2009, and $2.5 million in revenue in fiscal 2008.

Filing link

Note: OSIR shares have not moved as of yet on Japanese radiation, shares trading currently at $6.38 and in fact were much higher just a couple of months ago at $8.50 in mid Dec. 2010. So if investors get any hint like this 10K filing from Monday which was made available for our viewing today then it would not be surprising if (NASDAQ:OSIR) shares make its way back to $8.50 levels.